RUNX1 and acute myeloid leukemia: Of these, RUNX1-RT demonstrates a 30–40% lifetime risk of developing MDS/AML and ETV6-RT conferring a 20% lifetime risk of B-ALL with a 30% overall lifetime risk of hematological malignancy [1,5,31–33].